Jordyn Sava is an editor for Targeted Oncology.
INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer Recommended to Continue
March 30th 2022Tumor treating fields in combination with paclitaxel in patients with platinum-resistant ovarian cancer, has been recommended by an independent data monitoring committee to proceed to the final analysis based on data from the phase 3 INNOVATE-3 trial.
Venetoclax Consolidation Is Well Tolerated in Patients with Previously Untreated CLL
March 29th 2022Venetoclax consolidation after 12-cycles of treatment increases the duration of known toxicities and does not prevent the loss of minimal residual disease response and subsequent risk of disease relapse in patients with previously untreated chronic lymphocytic leukemia, a study shows.
Global Studies Evaluate Safety/Efficacy of TST001 for Locally Advanced or Metastatic Solid Tumors
March 25th 2022TST001 has shown to be safe in ongoing trials alone or in combination with chemotherapy and displayed encouraging anti-tumor activity signals in gastric cancer and other solid tumor patients expressing CLDN18.2.
FDA Discourages Marketing Authorization for Zandelisib in Patients With FL or MZL
March 25th 2022The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.
Tweet Chat Recap: Janjigian Discusses Biomarkers to Consider for Patients With Gastric Cancer
March 24th 2022In an interview with Targeted Oncology following the tweet chat, Yelena Y. Janjigian, discussed the key takeaways from the discussion and highlighted the biomarkers and standard of care for the patient in this case.
FDA Approves Pembrolizumab for Select Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
March 21st 2022Pembrolizumab is now an FDA-approved treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Type C Meeting With FDA Requested by Allarity to Discuss Dovitinib in Third-Line RCC
March 16th 2022Type C meeting with the FDA requested by Allarity to discuss potential clinical paths to support approval of dovitinib as a potential option in the third-line treatment of patients with renal cell carcinoma
Cabozantinib Plus Atezolizumab Shows No Overall Survival Benefit in HCC
March 15th 2022Cabozantinib in combination with atezolizumab shows no effect on survival compared to sorafenib in patients with previously untreated advanced hepatocellular carcinoma based on results from the final analysis of the phase 3 COSMIC-312 trial.
FDA Approves Olaparib CDx to Detect BRCA in High Risk Early Breast Cancer
March 14th 2022The FDA approved the BRACAnalysis CDx test for use as a companion diagnostic with adjuvant olaparib to identify patients with germline BRCA-mutated for patients with HER2 negative, high-risk early-stage breast cancer.
Ribociclib Plus Letrozole Extends Survival in Patients With Metastatic Breast Cancer
March 11th 2022Ribociclib plus letrozole demonstrated statistically significant improvement in overall survival with the combination in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.
Promising Results of Cabozantinib/Nivolumab in Non-Clear Cell RCC Could Guide Future Research
March 11th 2022In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD further discussed the results of the phase 2 trial of the combination of cabozantinib and nivolumab in patients with metastatic non-clear cell RCC and how it impacts the future of this space.
Pyrotinib/Capecitabine Shows Activity in HER2-Positive Breast Cancer with Brain Metastases
March 10th 2022Pyrotinib combined with apecitabine demonstrated promising activity in patients with HER2-positive breast cancer that have brain metastases, according to findings from the prospective phase 2 PERMEATE study.
Tisagenlecleucel Not Superior to SOC as 2L Treatment for Aggressive B-cell Lymphoma
March 10th 2022Significantly longer event-free survival was not demonstrated with tisagenlecleucel in the second-line setting when compared to standard-of-care second-line therapy in patients with refractory or early relapsed aggressive B-cell lymphoma.
FDA Grants Fast Track Designation to 7HP349 for Anti-PD-1 Metastatic Melanoma
March 9th 2022Fast track designation has been granted to 7HP349, in combination with a CTLA-4 inhibitor for the treatment of patients with unresectable or metastatic malignant melanoma following treatment failure with a PD-1 inhibitor.